SCHEMBL689135

SCHEMBL689135

CCCCCCCCCC(CCCCCCCC)C(C)(O)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.52
HSPD1 P10809 1/20 0.49
BLM P54132 1/20 0.49
HSPE1 P61604 1/20 0.49
GPR84 Q9NQS5 7/20 0.48
FFAR1 O14842 2/20 0.48
MAPT P10636 1/20 0.47
LCK P06239 1/20 0.47
PPARD Q03181 1/20 0.47
ZDHHC20 Q5W0Z9 1/20 0.47
ZDHHC2 Q9UIJ5 1/20 0.47
CA2 P00918 1/20 0.46
GRIK1 P39086 1/20 0.44
GRIK2 Q13002 1/20 0.44
FFAR4 Q5NUL3 1/20 0.44
ACE2 Q9BYF1 1/20 0.44
MEN1 O00255 1/20 0.44
HPGD P15428 1/20 0.44
RECQL P46063 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4344876 1.00 FDPS (0.52) FDPSHSPD1BLMHSPE1GPR84
Ammonia Solution, Strong SCHEMBL28668039 0.98 FDPS (0.50) FDPSHSPD1BLMHSPE1GPR84
SCHEMBL13684991 0.90 FDPS (0.46) FDPSHSPD1BLMHSPE1GPR84
SCHEMBL5606758 0.83 FDPS (0.40) FDPSHSPD1BLMHSPE1GPR84
SCHEMBL27747090 0.82 GPR84 (0.52) HSPD1BLMHSPE1GPR84FFAR1
SCHEMBL5702669 0.82 GPR84 (0.50) FDPSHSPD1BLMHSPE1GPR84
SCHEMBL688517 0.82 GPR84 (0.50) FDPSHSPD1BLMHSPE1GPR84
SCHEMBL16162180 0.81 GRIK1 (0.50) HSPD1BLMHSPE1GPR84FFAR1
Ammonia Solution, Strong SCHEMBL28649886 0.81 HSPD1 (0.46) FDPSHSPD1BLMHSPE1GPR84
SCHEMBL23197897 0.80 FDPS (0.52) FDPSHSPD1BLMHSPE1GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070122508-A1 Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease HELIXIR CO., LTD. (KR) 2007-05-31 US claimed
US-12616730-B2 Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof MEDIHELPLINE CO., LTD (KR) 2026-05-05 US disclosed
US-20230127213-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE TREATMENT OR ALLEVIATION OF SKIN ULCER AND THE USE THEREOF PARK, OK NAM (KR) 2023-04-27 US disclosed
US-20230103514-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE SKIN REGENERATION AND THE TREATMENT OR ALLEVIATION OF SKIN WOUND AND THE USE THEREOF MEDIHELPLINE CO., LTD (KR) 2023-04-06 US disclosed
US-20230100173-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR TLSP INHIBITION AND THE TREATMENT OR ALLEVIATION OF SKIN INFLAMMATORY DISEASE AND THE USE THEREOF MEDIHELPLINE CO., LTD (KR) 2023-03-30 US disclosed
EP-4117699-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE TREATMENT OR ALLEVIATION OF SKIN ULCER AND THE USE THEREOF Medihelpline Co., Ltd. (KR) 2023-01-18 EP disclosed
EP-4117698-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE SKIN REGENERATION AND THE TREATMENT OR ALLEVIATION OF SKIN WOUND AND THE USE THEREOF Medihelpline Co., Ltd. (KR) 2023-01-18 EP disclosed
EP-4117700-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR TLSP INHIBITION AND THE TREATMENT OR ALLEVIATION OF SKIN INFLAMMATORY DISEASE AND THE USE THEREOF Medihelpline Co., Ltd. (KR) 2023-01-18 EP disclosed
CN-115297879-A Topical composition comprising arillus longan combined crude drug extract for regenerating skin and treating or improving skin wound, and its application (株)美迪合伙来音 2022-11-04 CN disclosed
CN-115297880-A Topical composition comprising extract of crude drug comprising arillus longan for treating or improving skin ulcer, and its application (株)美迪合伙来音 2022-11-04 CN disclosed
US-20070122508-A1 Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease HELIXIR CO., LTD. (KR) 2007-05-31 US disclosed
WO-2007046636-A1 HERBAL COMPOSITION FOR PREVENTING AND IMPROVING BALDNESS KMSI CO., LTD (KR) 2007-04-26 WO disclosed
WO-2007004832-A1 COMPOSITION COMPRISING AN EXTRACT OF CRINUM ASIATICUM LINNE HAVING ANTI-ALLERGIC AND ANTI-INFLAMMATORY ACTIVITY BIOLAND LTD. (KR) 2007-01-11 WO disclosed
WO-2006093793-A2 COMPOSITIONS COMPRISING ACTINIDIA AND METHODS OF USE THEREOF EFFICAS, INC. (US) 2006-09-08 WO disclosed
WO-2006090939-A1 COSMETIC COMPOSITION COMPRISING BETA-FRUCTOSYL-L-ASCORBIC ACID FOR SKIN WHITENING BIOLAND LTD. (KR) 2006-08-31 WO disclosed
WO-2006016728-A1 COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA FOR PREVENTING AND TREATING BALDNESS DISORDERS AND SEBORRHEIC SKIN DISORDERS HELIXIR CO., LTD. (KR) 2006-02-16 WO disclosed
EP-1551433-A1 COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA AND RELATED SPECIES FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE AND NON-ALLERGIC INFLAMMATORY DISEASE Pangenomics Co., Ltd. (KR) 2005-07-13 EP disclosed
WO-2004096171-A1 SKIN WHITENING COSMETIC COMPOSITION COMPRISING THE EXTRACT OF MACHILUS THUNBERGII AND THE COMPOUNDS ISOLATED THEREFROM YEUNGNAM EDUCATIONAL FOUNDATION (KR) 2004-11-11 WO disclosed
WO-2004017982-A1 COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA AND RELATED SPECIES FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE AND NON-ALLERGIC INFLAMMATORY DISEASE PANGENOMICS CO., LTD (KR) 2004-03-04 WO disclosed
US-20040037909-A1 Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease VIROMED CO., LTD. (KR) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12616730-B2 Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof CUTA, VEGFA, MMP8 FDPS 4513/4885HSPD1 1196/4885BLM 2838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.